FDA Finalizes Gluten-Free Labeling Rule for Fermented and Hydrolyzed Foods
Today, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.
Continue ReadingToday, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.
Continue ReadingConcern has been expressed in the celiac disease community that the FDA’s temporary food labeling requirements during COVID-19 apply to gluten. The FDA confirmed that the introduction of unlabeled gluten is not allowed in regulated food products.
Continue ReadingWe are well on the way to assembling a grassroots advocacy team that can help make celiac disease a national priority in communities across the country
Continue ReadingMany people who suspect they have celiac disease choose to start a gluten-free diet right away, without a formal diagnosis. Here's why you shouldn't.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingTo ensure our community gets the representation it deserves, we are delighted to announce that we have retained Ben Nicholson, a consultant based in Washington, DC, to provide legislative, policy, and advocacy services for the Foundation.
Continue ReadingImmusanT, Inc., has announced that its therapeutic vaccine candidate, Nexvax2, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Continue ReadingOn December 12, 2017, the Food & Drug Administration (FDA) issued guidance to drug manufacturers to voluntarily label medications that do not contain gluten with the following statement: “Contains no ingredient made from a gluten-containing grain (wheat, barley, or rye).” The FDA granted a 60 day period to submit comments and suggestions regarding this draft…
Continue Reading“Fail faster” is a saying in drug research. In 2014, the Tufts Center for the Study of Drug Development estimated that the average cost of bringing a new drug through the development pipeline and Food and Drug Administration (FDA) approval process to market is $2.6 billion. More than 90 percent of all drugs being developed…
Continue ReadingThe Food & Drug Administration (FDA), on December 12, 2017, issued guidance to drug manufacturers to voluntarily label medications with a statement indicating that gluten-containing ingredients were not used to make the product, when such a statement is true. The Celiac Disease Foundation has been at the forefront of the fight to clearly label gluten…
Continue Reading